Bayer CEO confident firm can cope with Xarelto hit

Bayer recorded a decline in operating profit and high legal costs due to glyphosate claims in the first quarter. Despite challenges, the Group remains optimistic and confirms its annual targets.

Bayer CEO confident firm can cope with Xarelto hit

Bayer's CEO says newer product launches will offset the decline in sales of anticoagulant Xarelto over the course of 2025

Despite uncertainty from US customs policy, Bayer does not look as bad as feared. The share increased by 12 percent in the top. Dietmar Deffner talks about these and other Dax bills with stock market expert Jürgen Schmitt.

Smart weighing boosts Bayer’s production automation - Factory & Handling Solutions

The new supply centre of the agricultural chemical and pharmaceutical company Bayer in Hangzhou integrates weighing technology of Minebea Intec for precise mixing and homogenisation in Zone 2 hazardous areas. Features like smart calibration save time and labour, while seamless system integration ensures scalability. As a division of the Bayer Group, Bayer Crop Science holds a leading position in the global agricultural technology sector. Recentl…

German pharmaceutical and agrochemical giant Bayer, which is forecasting a difficult 2025, reported a net profit of €1.3 billion (slightly less in Swiss francs) for the first quarter on Tuesday. The 35% decline reflects lower sales in agrochemicals.

Germany's largest pharmaceutical company reported adjusted profit of 4.09 billion euros, down 7.4 percent from last year, but significantly higher than the expected 3.75 billion euros.